ASD Axis-Shield

RNS Number:3854Z
Axis-Shield PLC
1 August 2002


1 August 2002

              Axis-Shield announces agreement with Sangui Biotech


Axis-Shield plc ("Axis-Shield) today announces that it has reached a successful
agreement with Sangui Biotech Inc., USA regarding an alleged patent infringement
on Axis Shield's Carbohydrate Deficient Transferrin (%CDT) assay, used for the
detection of excessive alcohol consumption.  Sangui has agreed to cease selling
kits worldwide within 90 days. In addition, Sangui has agreed to sell
Axis-Shield its entire CDT business, which includes its customer lists,
trademarks and goodwill of its existing alcohol related products for US$100,000.

Commenting, Svein Lien, Chief Executive Officer said:

"This agreement strengthens the position of Axis-Shield as the market leader
within the field of diagnostics for alcohol related disease as it will give
further access to the lucrative US market."



Enquiries:

Axis-Shield plc                                       Tel: 00 47 922 893 23
Svein Lien, Chief Executive Officer


Financial Dynamics                                    Tel: +44 (0) 207 831 3113
Fiona Noblet






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

AGRMGGFNVMGGZZM

Axis-shield (LSE:ASD)
Historical Stock Chart
From Jul 2024 to Aug 2024

Axis-shield (LSE:ASD)
Historical Stock Chart
From Aug 2023 to Aug 2024